George Kelly Martin currently serves as Chairman of Transition Bio, Inc., a molecular condensates discovery company, a role which he has held since 2020, and as Vice Chairman of Ride Therapeutics, Inc., a molecular logistics company, a role which he has held since 2022. He has also served as Chairman of WaveBreak (formerly Wren Therapeutics, Inc.), a company that utilizes physical science and kinetics to create therapeutic solutions for protein misfolding diseases, since 2018.
Previously, George served as President and Chief Executive Officer of Radius Health, Inc., a bone and women’s health company, from 2020 to 2022. Prior to that, George served as Chief Executive Officer of Novan, Inc., a development-stage dermatology company, from 2018 to 2020. Prior to joining Novan, Inc., George was the Chief Executive Officer of Malin Corporation PLC, a life sciences investment company, from 2015 to 2017. George also served as Chief Executive Officer of Elan Corporation plc, an Ireland-based neurodegeneration research and development company, from 2003 to 2013. George’s business career started in finance and capital markets, having spent 21 years at Merrill Lynch & Co. Inc. At the time of his departure from Merrill Lynch in 2002, he was a member of the company’s Executive Operating Committee and his tenure included leadership oversight of four global divisions (debt markets, international equities, Information Technology, and International Private Banking). While at Merrill Lynch, George served multi-year assignments in both Tokyo and London. He previously served on the boards of directors of Questcor Pharmaceuticals, Immunocore Holdings, plc, and Kymab Ltd.
George received his B.A. in Politics from Princeton University.
What is George Kelly Martin's net worth?
The estimated net worth of George Kelly Martin is at least $1.00 million as of August 28th, 2024. Mr. Martin owns 247,176 shares of TriSalus Life Sciences stock worth more than $1,002,299 as of June 22nd. This net worth estimate does not reflect any other assets that Mr. Martin may own. Learn More about George Kelly Martin's net worth.
How do I contact George Kelly Martin?
Has George Kelly Martin been buying or selling shares of TriSalus Life Sciences?
George Kelly Martin has not been actively trading shares of TriSalus Life Sciences within the last three months. Most recently, George Kelly Martin sold 9 shares of the business's stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $5.50, for a transaction totalling $49.50. Following the completion of the sale, the director now directly owns 247,176 shares of the company's stock, valued at $1,359,468. Learn More on George Kelly Martin's trading history.
Who are TriSalus Life Sciences' active insiders?
Are insiders buying or selling shares of TriSalus Life Sciences?
During the last twelve months, TriSalus Life Sciences insiders bought shares 5 times. They purchased a total of 719,682 shares worth more than $1,804,176.38. During the last twelve months, insiders at the sold shares 11 times. They sold a total of 30,150 shares worth more than $119,849.35. The most recent insider tranaction occured on May, 15th when Director Mats Wahlstrom bought 60,000 shares worth more than $151,800.00. Insiders at TriSalus Life Sciences own 16.3% of the company.
Learn More about insider trades at TriSalus Life Sciences. Information on this page was last updated on 5/15/2026.